Trying to Heal Without ''Bringing Problems'': Navigating Cervical Precancer Stigma in a Phase I Clinical Trial in Western Kenya

BackgroundCervical cancer remains a leading cause of cancer-related deaths among women in low- and middle-income countries, particularly in sub-Saharan Africa. Sociocultural barriers including stigma significantly influence womens decisions around screening and treatment. ObjectiveTo explore how stigma influences womens experiences with cervical precancer care in the context of emerging self-administered topical therapies. DesignA qualitative approach using convenience sampling. MethodsSeventeen in-depth interviews were conducted between 2024 and 2025 in Kisumu, Kenya, with women who had been diagnosed with cervical precancer. Participants were recruited to self-administer intravaginal artesunate in a Phase I clinical trial, and interviews explored their experiences. Thematic analysis was conducted using the Health Stigma and Discrimination Framework. ResultsAll women discussed experiences indicative of enacted, anticipated, and internalized stigmas related to partner blame, disclosure, and imagining the diagnosis as an imminent death sentence. These stigmas were driven and facilitated by poverty and limited health care access, embarrassment around sexual health, community fears of cervical cancer death, patriarchal norms, and cervical precancers disproportionate burden on women. Women with cervical precancer feel "marked" by medication usage, clinic visits, community expectations of a "cancer" appearance, or painful sexual intercourse. By exercising relational autonomy, women in this trial were able to navigate stigmas around sexual health and overcome the debilitating fear of death. They were ultimately able to complete the self-administered artesunate treatment course and initiate conversations in their communities to address stigmas around cervical precancer treatment. Nevertheless, stigmas caused delays to screening and treatment among some participants, while others experienced intimate partner violence or conflict during artesunate treatment. ConclusionStigmas around cervical precancer, artesunate usage, and abstinence requirements can deeply impact womens social experiences, intimate partnerships, and mental health. Future trials of self-administered therapies should integrate stigma reduction strategies developed in collaboration with participants and survivors. ClinicalTrials.gov NCT06165614, https://clinicaltrials.gov/study/NCT06165614